Metformin and Long COVID; Lp(a) Lowering for Cardiovascular Disease
(MedPage Today) -- TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of Texas Tech Health El Paso, look at the top medical...
A new study published in the New England Journal of Medicine unveiled that lowering Lp(a) levels, a risk factor for atherosclerotic cardiovascular disease, did not result in a decrease in cardiovascular events. Pelacarsen, an antisense oligonucleotide, was administered subcutaneously to 4,100 patients on a monthly basis. The study concluded that pelacarsen led to a more than 70% reduction in lipoprotein(a) levels, but there were no significant differences in death, heart attacks, strokes, or coronary revascularization between the pelacarsen group and the placebo group over a period of 4.7 years.
Rewritten by urgent.news; may contain errors — check the original.